The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. OBJECTIVE: To conduct a within-patient comparison of the prognostic value of 6 multigene signatures in women with early ER-positive breast cancer who received endocrine therapy for 5 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective biomarker analysis included 774 postmenopausal women with ER-positive ERBB2 (formerly HER2)-negative breast cancer. This analysis was performed as a preplanned secondary study of data from the Anastrozole or Tamoxifen Alone or Combined randomized clinical trial comparing 5-year treatment with anastrozole vs tamoxifen with 10-year follow-up data. The signatures included the Oncotype Dx recurrence score, PAM50-based Prosigna risk of recurrence (ROR), Breast Cancer Index (BCI), EndoPredict (EPclin), Clinical Treatment Score, and 4-marker immunohistochemical score. Data were collected from January 2009, through April 2015. MAIN OUTCOMES AND MEASURES: The primary objective was to compare the prognostic value of these signatures in addition to the Clinical Treatment Score (nodal status, tumor size, grade, age, and endocrine treatment) for distant recurrence for 0 to 10 years and 5 to 10 years after diagnosis. Likelihood ratio (LR) statistics were used with the χ2 test and C indexes to assess the prognostic value of each signature. RESULTS: In this study of 774 postmenopausal women with ER-positive, ERBB2-negative disease (mean [SD] age, 64.1 [8.1] years), 591 (mean [SD] age, 63.4 [7.9] years) had node-negative disease. The signatures providing the most prognostic information were the ROR (hazard ratio [HR], 2.56; 95% CI, 1.96-3.35), followed by the BCI (HR, 2.46; 95% CI, 1.88-3.23) and EPclin (HR, 2.14; 95% CI, 1.71-2.68). Each provided significantly more information than the Clinical Treatment Score (HR, 1.99; 95% CI, 1.58-2.50), the recurrence score (HR, 1.69; 95% CI, 1.40-2.03), and the 4-marker immunohistochemical score (HR, 1.95; 95% CI, 1.55-2.45). Substantially less information was provided by all 6 molecular tests for the 183 patients with 1 to 3 positive nodes, but the BCI (ΔLR χ2 = 9.2) and EPclin (ΔLR χ2 = 7.4) provided more additional prognostic information than the other signatures. CONCLUSIONS AND RELEVANCE: For women with node-negative disease, the ROR, BCI, and EPclin were significantly more prognostic for overall and late distant recurrence. For women with 1 to 3 positive nodes, limited independent information was available from any test. These data might help oncologists and patients to choose the most appropriate test when considering chemotherapy use and/or extended endocrine therapy. TRIAL REGISTRATION: isrctn.com Identifier: ISRCTN18233230.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674 · cited 1×
“Study Design and Patients In this preplanned comparative analysis, tumor blocks from the TransATAC studywere used from patients with hormone receptor–positiveearly-stagebreast cancer treatedwith5years of tamoxifen or anastrozole in the ATAC randomized clinical trial.(12)Microdissectionof the tumors andRNAextractionwer…”
MethodSelf-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Self-citationFilipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0926 · Cited by 733
Self-citationExtending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 644
Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., Ferree, S., Storhoff, J., Schaper, C., & Cuzick, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1558 · Cited by 621
Self-citationDuffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Sgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Self-citationon behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Dubsky, P., Brase, J. C., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.671 · Cited by 350
Self-citationMa, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5026 · Cited by 315
Self-citationSestak, I., Cuzick, J., Dowsett, M., Lopez-Knowles, E., Filipits, M., Dubsky, P., Cowens, J. W., Ferree, S., Schaper, C., Fesl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6894 · Cited by 249
Self-citationSgroi, D. C., Carney, E., Zarrella, E., Steffel, L., Binns, S. N., Finkelstein, D. M., Szymonifka, J., Bhan, A. K., Shepherd, L. E., Zhang, Y., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt146 · Cited by 229
Self-citationZhang, Y., Schnabel, C. A., Schroeder, B. E., Jerevall, P.-L., Jankowitz, R. C., Fornander, T., Stål, O., Brufsky, A. M., Sgroi, D., & Erlander, M. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0804 · Cited by 226
Self-citationJerevall, P.-L., Ma, X.-J., Li, H., Salunga, R., Kesty, N. C., Erlander, M. G., Sgroi, D. C., Holmlund, B., Skoog, L., Fornander, T., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.145 · Cited by 220
Self-citationFilipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stöger, H., Jakesz, R., Bago-Horvath, Z., Dietze, O., Regitnig, P., Gruber-Rossipal, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1845 · Cited by 215
Self-citationBuus, R., Sestak, I., Kronenwett, R., Denkert, C., Dubsky, P., Krappmann, K., Scheer, M., Petry, C., Cuzick, J., & Dowsett, M. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw149 · Cited by 206
Self-citationBlok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., Liefers, G.-J., Nortier, J. W. R., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 200
Tjan‐Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., de Graaf, H., Honkoop, A. H., Erdkamp, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30600-9 · Cited by 172
Tang, G., Cuzick, J. M., Costantino, J. P., Dowsett, M., Forbes, J., Crager, M., Mamounas, E. P., Shak, S., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3714 · Cited by 135
Self-citationSorting Out Breast-Cancer Gene Signatures
Massagué, J. (2007) · New England Journal of Medicine · doi:10.1056/nejme068292 · Cited by 126
Cited by
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Breast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00069 · Cited by 365
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Metadata
- Authors
- Sestak, I., Buus, R., Cuzick, J., Dubsky, P., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D., Schnabel, C., Baehner, F. L., Mallon, E., & Dowsett, M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-04-01
- Volume
- 4
- Issue
- 4
- Pages
- 545
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2788523770
- Cited by
- 318
- References
- 26
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.